^
Association details:
| Biomarker: | PIK3CA E545X |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Piqray (alpelisib) (PIK3CA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Excerpt:
Treatment with alpelisib–fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously….Figure 2. Subgroup Analysis of Progression-free Survival in the Cohort with PIK3CA-Mutated Cancer.
Secondary therapy:
fulvestrant
Trial ID:
